The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric Qatari Patients Affected with Classical B6 Non-responsive Homocystinuria.

NCT06622577 | Not Yet Recruiting

• 1 other identifier: MRC-01-23-734
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Classical homocystinuria (HCU) is an autosomal recessive disorder caused by the deficiency of an enzyme cystathionine β-synthase (CβS) that affects the catabolic pathway of the amino acid methionine (Met) which leads to an accumulation of high levels of methionine and Homocysteine causing complications in the multi system. Therefore, a strict dietary management is crucial to maintain good biochemical control, growth parameters and avoid complications. The main objective would be to analyze the impact of the Met restricted diet on growth parameters, biochemical markers and long-term complications in patients up to 18 years. In addition, the efficacy of dietary management with additional cysteine (Cys) supplementation for the patients up to 18 years would also be examined. The participants of the study would be recruited from the metabolic and genetics clinic in Hamad General Hospital (HGH), Qatar. All Qatari participants with confirmed diagnosis of HCU \<18 years of age will be included in the study. A mixed method study design would be used which include a cross sectional study design to assess the impact of methionine restricted diet on outcome variables and a single arm interventional study to analyze the effect of additional cysteine supplementation in patients from birth to 18 years. For the retrospective study, all the required data would be retrieved from electronic record from the Cerner of HMC and would be stored in a local drive with password protection. Further, all the eligible participants would be prospectively followed to supplement additional cysteine for the period of 6 months. The collected data will be statistically analyzed using the "SPSS windows version 22.0 software. The study would improve better understanding of dietary management through the identified outcomes. The outcome of Cys supplementation will improve the protein tolerance, biochemical parameters, growth parameters and may standardize the Cys supplementation.

Conditions

Classical Homocystinuria

Keywords

Methionine; Homocystinuria; cysteine

Outcome Measures

Primary Outcomes (1)

• improvement of the biochemical parameters specifically homocysteine and methionine levels

  Biochemical Parameters: Description: The primary outcome will assess the improvement in biochemical parameters, specifically homocysteine (umol/l) and methionine levels(umol/l), in patients with Homocystinuria (HCU) following Cysteine(Cys) supplementation. Measurement Tool: Blood tests will be used to measure the levels of homocysteine and methionine.

  Six months

Secondary Outcomes (1)

• Improvement of growth parameters including weight, Height and BMI

  six month

Study Arms (1)

dietary management with additional Cysteine supplementation

EXPERIMENTAL

Dietary Supplement: Cysteine

Interventions

Cysteine DIETARY_SUPPLEMENT

Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.

Also known as: single arm interventional study

dietary management with additional Cysteine supplementation

Eligibility Criteria

• Age: 1 Day - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• All the patients with a confirmed diagnosis of HCU by molecular and biochemical testing who are either diagnosed through NBS or LD who are following the diet
• Both male and female gender from birth to 18 years

You may not qualify if:

• ✔ Patients with Pyridoxine responsive- homocystinuria
• Patients who are solely on medication without any dietary intervention ✔ Non-Qatari Patients with a confirmed diagnosis of HCU

Sponsors & Collaborators

• Hamad Medical Corporation: lead

Study Sites (1)

Department of dietetics and Nutrition

Doha, Qatar, 00000, Qatar

Location

MeSH Terms

Conditions

Homocystinuria

Interventions

Cysteine

Condition Hierarchy (Ancestors)

Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Hyperhomocysteinemia; Amino Acid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Amino Acids, Sulfur; Sulfur Compounds; Organic Chemicals; Sulfhydryl Compounds; Amino Acids, Neutral; Amino Acids; Amino Acids, Peptides, and Proteins

Central Study Contacts

Kala darling, Masters in Nutrition

CONTACT

800-555-5555; kdanial@hamad.qa

Tawfeg ben omran, MD

CONTACT

800-555-5555; TOMRAN@hamad.qa

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 26, 2024
• First Posted: October 2, 2024
• Study Start: December 1, 2024
• Primary Completion: July 1, 2025
• Study Completion: August 31, 2025
• Last Updated: October 2, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

QA (1)